Dr. Reddy's Laboratories is working on four new products which are in the final stage besides some early stage drugs. The products' segment focuses on research and development, and commercialisation of different formulations. The new compounds are in the therapeutic areas of paediatrics, dermatology, haematology-oncology.
DFD-11(Xeglyze) in paediatrics area is intended for treatment of head lice in patients six months of age or older. PPC-06 (Tepilamide Fumarate) in dermatologyis for the treatment of plaque psoriasis in patients 18 years of age or older. Compound E7777 is intended to be used in the treatment of Cutaneous T Cell Lymphoma while DFD-29 (Low dose minocycline) is aimed at Papulopustular rosacea.
As of March 31, 2020, the Company have had four late-stage projects at various stages of development ranging from products that have completed Phase-2 clinical trials to products that are undergoing investigation for US FDA approval.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1620.50 |
Dr. Reddys Lab | 6171.85 |
Cipla | 1494.65 |
Zydus Lifesciences | 1013.75 |
Lupin | 1617.85 |
View more.. |